Arbutus Biopharma Reports Strong Revenue Growth in Q2 2025

Arbutus Biopharma ( (ABUS) ) has released its Q2 earnings. Here is a breakdown of the information Arbutus Biopharma presented to its investors.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, particularly chronic hepatitis B, using its proprietary RNA interference and PD-L1 inhibitor technologies. In its latest earnings report for the quarter ending June 30, 2025, Arbutus Biopharma highlighted a significant increase in revenue, driven primarily by collaborations and licenses, with total revenue reaching $10.7 million compared to $1.7 million in the same quarter last year. Key financial metrics revealed a net income of $2.5 million, a notable improvement from a net loss of $19.8 million in the previous year, attributed to reduced operating expenses and increased collaboration revenue. The company also reported a restructuring charge related to workforce reduction and the closure of its headquarters, which contributed to a decrease in operating expenses. Looking ahead, Arbutus Biopharma remains focused on advancing its clinical programs and defending its intellectual property, with management expressing confidence in its cash resources to support operations for the next 12 months.